By Fineline Cube 
Shenzhen-based XtalPi Holdings Limited (HKG: 2228), an AI-driven pharmaceutical company, announced the complete acquisition of UK-headquartered Liverpool ChiroChem Ltd. (LCC). This strategic move significantly enhances XtalPi’s “AI + Robotics” intelligent autonomous experimentation platform for chemical space exploration.
Liverpool ChiroChem’s Expertise
Founded in 2014 as a spin-off from the University of Liverpool, LCC specializes in novel molecular design and synthesis technologies. The company has particular expertise in chiral molecules, which are crucial in pharmaceutical development due to their unique chemical properties and applications.
PACE Platform Integration
LCC’s proprietary PACE (Parallel Automated Chiral Engine) platform integrates AI software with automation technology. This innovative system enables virtual screening of target molecules from chiral chemical libraries containing over 100 million compounds. It also facilitates efficient synthesis through automated equipment and rapid transition to physical testing, significantly accelerating the drug discovery process.-Fineline Info & Tech